Cargando…

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more...

Descripción completa

Detalles Bibliográficos
Autores principales: Skolnik, Neil, Del Prato, Stefano, Blonde, Lawrence, Galstyan, Gagik, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004501/
https://www.ncbi.nlm.nih.gov/pubmed/33620694
http://dx.doi.org/10.1007/s12325-020-01614-5
_version_ 1783671922423234560
author Skolnik, Neil
Del Prato, Stefano
Blonde, Lawrence
Galstyan, Gagik
Rosenstock, Julio
author_facet Skolnik, Neil
Del Prato, Stefano
Blonde, Lawrence
Galstyan, Gagik
Rosenstock, Julio
author_sort Skolnik, Neil
collection PubMed
description Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more people to reach HbA(1c) targets compared with separate administration of iGlar or Lixi. The purpose of this review is to help clinicians understand treatment intensification using iGlarLixi by presenting typical clinical scenarios supported by research evidence. These cases will focus on individuals with T2D inadequately controlled by oral antihyperglycemic drugs, basal insulin, or glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and take into consideration T2D duration, body mass index, incidence of adverse events, and regimen simplicity. Clinical evidence on the efficacy, effectiveness, and safety of iGlarLixi from randomized controlled trials and real-world studies will be discussed in the context of these cases.
format Online
Article
Text
id pubmed-8004501
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-80045012021-04-16 Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes Skolnik, Neil Del Prato, Stefano Blonde, Lawrence Galstyan, Gagik Rosenstock, Julio Adv Ther Review Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more people to reach HbA(1c) targets compared with separate administration of iGlar or Lixi. The purpose of this review is to help clinicians understand treatment intensification using iGlarLixi by presenting typical clinical scenarios supported by research evidence. These cases will focus on individuals with T2D inadequately controlled by oral antihyperglycemic drugs, basal insulin, or glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and take into consideration T2D duration, body mass index, incidence of adverse events, and regimen simplicity. Clinical evidence on the efficacy, effectiveness, and safety of iGlarLixi from randomized controlled trials and real-world studies will be discussed in the context of these cases. Springer Healthcare 2021-02-23 2021 /pmc/articles/PMC8004501/ /pubmed/33620694 http://dx.doi.org/10.1007/s12325-020-01614-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Skolnik, Neil
Del Prato, Stefano
Blonde, Lawrence
Galstyan, Gagik
Rosenstock, Julio
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
title Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
title_full Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
title_fullStr Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
title_full_unstemmed Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
title_short Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
title_sort translating iglarlixi evidence for the management of frequent clinical scenarios in type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004501/
https://www.ncbi.nlm.nih.gov/pubmed/33620694
http://dx.doi.org/10.1007/s12325-020-01614-5
work_keys_str_mv AT skolnikneil translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes
AT delpratostefano translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes
AT blondelawrence translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes
AT galstyangagik translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes
AT rosenstockjulio translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes